文献速递肝肾功能剂量调整特殊人群用药药物相互作用

BTK抑制剂阿可替尼及其活性代谢物的群体药代动力学

Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies.
PubMed 文献 · Clin Pharmacokinet · 2019-01-01

该分析基于6项B细胞恶性肿瘤患者I/II期试验和7项健康志愿者I期试验的浓度-时间数据,采用非线性混合效应模型表征阿可替尼及其代谢物ACP-5862的群体药代动力学。阿可替尼表观清除率为169 L/h(95%CI 159-175),ACP-5862清除率为21.9 L/h(95%CI 19.5-24.0);在75-250 mg范围内清除率随剂量增加而降低的幅度较小,所考察的协变量均未导致暴露出现有临床意义的变化,无需进行剂量调整。

要点

  • 阿可替尼表观清除率为169 L/h(95%CI 159-175),代谢物ACP-5862为21.9 L/h(95%CI 19.5-24.0)。
  • 在75-250 mg范围内,阿可替尼清除率随剂量增加而降低的幅度较小。
  • 所考察的内在和外在协变量均未导致暴露出现有临床意义的变化,无需调整剂量。

核心结论

  • 阿可替尼及其代谢物ACP-5862的药代动力学特征得到充分表征,所考察的协变量均无需进行剂量调整。

研究设计与样本

  • 数据来自6项B细胞恶性肿瘤成人患者I/II期试验和7项健康志愿者I期试验,剂量范围15-400 mg,采用非线性混合效应模型分析。
  • 共获得11,196份阿可替尼和1068份ACP-5862浓度-时间样本。
  • 基础模型参数按体重缩放并归一化至70 kg(清除率和分布容积的固定指数分别为0.75和1)。
  • 采用全协变量方法评估剂量、健康组/疾病状态、肝肾功能损害、使用抗酸剂、种族和性别的影响。

主要发现

  • 两种分析物均采用二室处置模型充分描述,阿可替尼吸收采用序贯零级和一级速率常数及滞后时间表征。
  • 阿可替尼表观清除率为169 L/h(95%CI 159-175)。
  • 相对于100 mg剂量组,15 mg和400 mg剂量组的表观清除率分别高1.44倍和低0.77倍。
  • ACP-5862清除率为21.9 L/h(95%CI 19.5-24.0),代谢分数固定为0.4。
  • 阿可替尼中央和外周分布容积分别为33.1 L(95%CI 24.4-41.0)和226 L(95%CI 149-305);ACP-5862分别为38.5 L(95%CI 31.6-49.2)和38.4 L(95%CI 32.3-47.9)。

关键数值与推荐

  • 阿可替尼表观清除率为169 L/h(95%CI 159-175)。
  • ACP-5862清除率为21.9 L/h(95%CI 19.5-24.0),代谢分数固定为0.4。
  • 相对于100 mg剂量组,15 mg和400 mg剂量组的表观清除率分别高1.44倍和低0.77倍。
  • 阿可替尼中央和外周分布容积分别为33.1 L(95%CI 24.4-41.0)和226 L(95%CI 149-305)。
  • ACP-5862中央和外周分布容积分别为38.5 L(95%CI 31.6-49.2)和38.4 L(95%CI 32.3-47.9)。

临床怎么用

  • 基于所考察的内在和外在协变量,阿可替尼无需进行剂量调整。
  • 在75-250 mg范围内,清除率随剂量增加而降低的幅度较小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Bruton tyrosine kinase (BTK) is a key component of B-cell receptor signalling, critical for cell proliferation. Acalabrutinib, a selective, covalent BTK inhibitor, recently received an accelerated approval in relapsed/refractory mantle cell lymphoma. This analysis characterized the population pharmacokinetics (PK) of acalabrutinib and its metabolite ACP-5862. METHODS: Data were obtained from six phase I/II trials in adult patients with B-cell malignancy and seven phase I trials in healthy volunteers. Pooled concentration-time data, at dose levels ranging from 15 to 400 mg, were analysed using non-linear mixed-effects modelling. Base model parameters were scaled with body weight and normalized to 70 kg (fixed exponents: 0.75 and 1 for clearance and volumes, respectively). A full covariate approach was used to evaluate any relevant effects of dose, health group/disease status, hepatic and renal impairment, use of acid-reducing agents, race and sex. RESULTS: A total of 11,196 acalabrutinib and 1068 ACP-5862 concentration-time samples were available. The PK of both analytes were well described using two-compartment disposition models. Acalabrutinib absorption was characterized using sequential zero- and first-order constants and a lag time. Apparent clearance (CL/F) of acalabrutinib was 169 L/h (95% CI 159-175). Relative to the 100 mg dose group, the 15 and 400 mg dose groups showed a 1.44-fold higher and 0.77-fold lower CL/F, respectively. The clearance for ACP-5862 was 21.9 L/h (95% CI 19.5-24.0). The fraction metabolized was fixed to 0.4. The central and peripheral volumes of distribution were 33.1 L (95% CI 24.4-41.0) and 226 L (95% CI 149-305) for acalabrutinib, and 38.5 L (95% CI 31.6-49.2) and 38.4 L (95% CI 32.3-47.9) for ACP-5862. None of the investigated covariates led to clinically meaningful changes in exposure. CONCLUSION: The PK of acalabrutinib and its metabolite ACP-5862 were adequately characterized. Acalabrutinib CL/F decreased with increasing dose, but the trend was small over the 75-250 mg range. No dose adjustment was necessary for intrinsic or extrinsic covariates.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Edlund H, Lee SK, Andrew MA, et al. Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies. Clin Pharmacokinet. 2019. PMID: 30556110. doi:10.1007/s40262-018-0725-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。